Includes bibliographical references and index.

Description based on print version record and CIP data provided by publisher.

Table of Contents; Wiley Series on Technologies for the Pharmaceutical Industry; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; General Principles for Success; Notes; 2: Divided We Fall; Challenges; Collaboration Models

Examples of Successful Biomedical CollaborationsPrinciples of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People Innovate?; How Do We Encourage Innovation?; Why Is Innovation Important?; Warnings Regarding Innovation in Drug Discovery; Open Source Models; Nonprofit Models; Recommendations; References; 4: The Changing Face of Innovation in Drug Discovery; Introduction; Core Objectives of the Drug Discovery Process

Major Innovations in Technology Have Advanced Drug DiscoveryAn Important Trend: Academic and Pharmaceutical Organizations Are Collaborating in Support of Drug Discovery; Future Perspectives: Where Is Innovation Leading?; References; 5: Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives; Pharmaceutical Industry's Perspective; Academia's Perspective; Open (Collaborative) Innovation: A New Business Model; Drug Discovery through Collaborations; Drug Discovery through Consortia; Drug Discovery through Repurposing Strategies

Probe Discovery in Public DomainEffective Management of Academia-Pharma Collaborations; Concluding Remarks; References; Notes; 6: A Perspective on the Evolution of Collaborative Drug Discovery and Future Challenges; Evolution of Collaborative Drug Discovery; Challenges for Collaborative Drug Discovery; Conclusion; References; Part II: Governmental Initiatives Accelerate Precompetitive Collaboration; 7: The Value of University-Industry Partnerships; Guiding Principles for University-Industry Collaborations; The Johnson Continuum; Role of Cocreation: Companies, Government, and Universities

Funding for Collaborations with AcademiaNew Initiatives to Transform University-Industry Collaborations; Issues Affecting University-Industry Collaborations; Differences between Large- and Small-/Medium-Sized Companies; Large Companies Share Certain Characteristics; Small- and Medium-Sized Enterprises (SMEs) Offer a Contrasting Perspective; The National Academies' University-Industry Demonstration Partnership; Strategies for Building High-Value, High Return U-I Partnerships; Conclusion; Note on this Chapter; Note; References